Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

  title={Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology},
  author={John P.M. Finberg and José Martin Rabey},
  journal={Frontiers in Pharmacology},
  • J. Finberg, J. Rabey
  • Published 18 October 2016
  • Biology, Medicine, Chemistry, Psychology
  • Frontiers in Pharmacology
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which substrates and inhibitor molecules are metabolized, or inhibit metabolism of substrates, respectively. Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clinical use has been limited by their side… 

Figures and Tables from this paper

Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

This review summarizes the most important aspects regarding the development and clinical use of MAO inhibitors, going through mechanistic and structural details, new indications, and future perspectives.

Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively

Practical advice is given in terms of dietary restrictions, interactions with other medications, and how prescribers can stop and switch MAOIs, both within the drug class and outside of it.


The review emphasized the pharmacological aspect, side effect, and neuroprotective effect of Selegiline and Rasagiline on Parkinson’s disease.

Methylene blue and its analogues as antidepressant compounds

Methylene Blue (MB) is considered to have diverse medical applications and is a well-described treatment for methemoglobinemias and ifosfamide-induced encephalopathy. In recent years the focus has

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

  • J. Finberg
  • Biology, Medicine
    Journal of Neural Transmission
  • 2018
The scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson’s disease are described.

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases.

The potential of herbal MAO inhibitors as well as their associated mechanism of action are discussed, with an aim to foster future research on herbal MAo inhibitors as potential treatment for neurological diseases.

Kinetics, mechanism, and inhibition of monoamine oxidase

The kinetic behaviour of MAO A and B and the kinetic evaluation of reversible inhibitors that transiently decrease catalysis are summarized and the mechanism of irreversible inhibition by hydrazine, cyclopropylamine, and propargylamine drugs will be discussed.



Clinical applications of MAO-inhibitors.

The preclinical and clinical effects of selegiline with regard to neuroprotection are highlightened and the conclusion is drawn that there is good evidence for a clinical neuroprotective capacity based on the assumption that the 50 percent recovery of MAO-B is obtained already after a 10 days withdrawal of se LEGiline.

MAO-inhibitors in Parkinson's Disease

In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.

Selective inhibitors of monoamine oxidase type B and the "cheese effect".

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.

It was concluded that (-)-deprenyl is an effective antidepressant in a dose range where it is distinguished by the absence of many of the side effects typical of nonselective MAO inhibitors.

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

Deprenil is an inhibitor of MAO-B and is characterized by less frequent side effects, which can be eliminated by lowering the dosage of Deprenil, which is an excellent drug for preventing these.

Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression

This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second

Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.

1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B.

Pharmacology of selegiline

There is no clear knowledge regarding an understanding of the reported effects of selegiline on the progression of Parkinson's disease, but some evidence suggests both an indirect (via induction of radical-scavenging enzymes) and a direct antioxidant function for seLegiline.